1st Quarter - Report

WALGREEN COMPANY for WALGREEN COMPANY

Firm
Client
Income
—
Expenses
$590,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

S. 336 and H.R. 684 - the "Marketplace Fairness Act," all provisions regarding authorizing each state under the Streamlined Sales and Use Tax Agreement (the multistate agreement for the administration and collection of sales and use taxes adopted on November 12, 2002) to require all sellers not qualifying for a small-seller exception (applicable to sellers with annual gross receipts in total U.S. remote sales not exceeding $1 million) to collect and remit sales and use taxes.

LobbyistCovered position, as disclosed
DEBBIE GARZA —
ALETHIA JACKSON —
EDWARD KALETA —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 684 (113th), S. 336 (113th)

Health Issues HCR

S. 621 and H.R. 1285 - the "Safe Prescribing Act of 2013," all provisions regarding amendment of the Controlled Substances Act to make any substance containing hydrocodone a Schedule II drug.

LobbyistCovered position, as disclosed
DEBBIE GARZA —
ALETHIA JACKSON —
EDWARD KALETA —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 621 (113th), H.R. 1285 (113th)

Medicare/Medicaid MMM

S. 557 and H.R. 1024 - the "Medication Therapy Management Empowerment Act," amending the Medicare Modernization Act to expand the eligibility for beneficiaries for access to Medication Therapy Management (MTM) in Medicare Part D.Issues related to related to pharmacists recognized as health care providers federally. No specific legislation Issues related to Pharmacy Benefit Managers (PBM) activities around disclosures and audit protections. No legislation.

LobbyistCovered position, as disclosed
DEBBIE GARZA —
ALETHIA JACKSON —
EDWARD KALETA —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1024 (113th), S. 557 (113th)

Pharmacy PHA

Issues related to pharmacy prescription compounding and Food and Drug Administration oversight. No legislation.

LobbyistCovered position, as disclosed
DEBBIE GARZA —
ALETHIA JACKSON —
EDWARD KALETA —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.